" class="no-js "lang="en-US"> LoQus23 Therapeutics - Medtech Alert
Thursday, October 09, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
LoQus23 Therapeutics | Pharmtech Focus

LoQus23 Therapeutics

About LoQus23 Therapeutics

LoQus23 Therapeutics

LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.

Related Story

Fundraising

 LoQus23 Therapeutics Exits Stealth with £11.5 Million Seed Financing from the Dementia Discovery Fund and Novartis Venture Fund | Pharmtech Focus

LoQus23 Therapeutics Exits Stealth with £11.5 Million Seed Financing from the Dementia Discovery Fund and Novartis Venture Fund

November 23 2021

LoQus23 Therapeutics Ltd. (‘LoQus23’), a company discovering small molecule therapies that target aberrant DNA mismatch […]